Zamira Vanessa Diaz Riascos I am a researcher in the Drug Delivery and Targeting (DDT) group, and our research is focused on improving the treatment of minority diseases such and cancer using nanomedicine in animal models. In addition, I am responsible for the in vivo section of the Functional Validation & Preclinical Research (FVPR) platform of the Nanbiosis U20. Institutions of which they are part Senior researcher Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) Vall Hebron Institut de Recerca Email Zamira Vanessa Diaz Riascos Email Institutions of which they are part Senior researcher Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) Vall Hebron Institut de Recerca I am a researcher in the Drug Delivery and Targeting (DDT) group, and our research is focused on improving the treatment of minority diseases such and cancer using nanomedicine in animal models. In addition, I am responsible for the in vivo section of the Functional Validation & Preclinical Research (FVPR) platform of the Nanbiosis U20.
I obtained the degree of Biology from the Autonomous University of Barcelona (Spain) in 2007. Also, in the same year I obtained the title of Official Master's Degree in Advanced Genetics from the Autonomous University of Barcelona. During my PhD in the laboratory of Dr. Gabriel Capellà (ICO-IDIBELL, Barcelona, Spain), I implanted an orthotopic mouse model, perpetuating human pancreatic ductal adenocarcinoma (PDAC) tissues. I gained a strong understanding of mouse surgery with considerable experience including: handling of clinical human samples, processing of samples derived from mouse models, and data analysis. My project focused on a molecular biology study characterizing the most frequent genes involved in this type of tumor. In addition, during my PhD I investigated the role of microRNAs, the miR-200 family, and ZEBs in PDAC primary tumors, patient-derived xenografts, and in cells that overexpress miR-200 by lentivirus transduction. I did an 11-month stay at the “Centre de recherches en cancerologie” of Toulouse, Inserm-Université Toulouse, France, under the supervision of Dr. Pierre Cordelier. Where I was trained to produce lentivirus, development of experiments with cell cultures and Western Blot analysis. Since 2016, I have been in the area of Functional Validation & Preclinical Research (FVPR) and I am currently responsible for the in vivo section, I also have a postdoctoral position in the Drug Delivery and Targeting group led by Dr. Abasolo. I have participated in multiple projects international and national studies using animal models for the validation of new therapeutic targets and new components of nanomedicine for cancer therapy. I recently participated in the development of the preclinical part of the Nocanther project, where magnetic hyperthermia in combination with chemotherapy was studied in a mouse model for the treatment of advanced pancreatic cancer. Nocanther is currently in the clinical phase. In addition, in these last 5 years, I have gained great experience in the field of lysosomal diseases, such as Fabry disease. In this case, I have studied the liposomes and extracellular vesicles as transport agents for the enzyme absent in this disease (GLA). I have carried out studies on the toxicity, biodistribution and efficacy of these nanoparticles in a GLA-deficient mouse model, obtaining published results. I am currently managing and maintaining a colony of transgenic mice. I also participate in a European project (Mimickey) that studies the disease of pycnodysosotosis (cathesin deficiency). In addition, I have extensive experience in experimental imaging models and functional applications of bioluminescent or fluorescent non-invasive optical imaging. Work under ISO9001 conditions.
Projects Mejora del tratamiento de las enfermedades de depósito lisosomal mediante vehículos nanométricos optimizados. IP: Ibane Abasolo Olaortua Collaborators: Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael Funding agency: Instituto de Salud Carlos III Funding: 116160 Reference: PI18/00871 Duration: 01/01/2019 - 30/06/2022 Smart-4-Fabry: Smart multifunctional GLA-nanoformulation for Fabry disease IP: - Collaborators: Ibane Abasolo Olaortua, Simon Schwartz Navarro, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua, Ibane Abasolo Olaortua Funding agency: EUROPEAN COMMISSION Funding: 266300.8 Reference: SMART4FABRY_H2020NMBP2016 Duration: 01/01/2017 - 31/12/2020 NoCanTher: Nanomedicine Upscaling for Early Clinical Phases of Multimodal Cancer Therapy IP: Simon Schwartz Navarro Collaborators: Ibane Abasolo Olaortua, Joaquin Seras Franzoso, Tamara Del Rio Higueras, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Olga Sánchez- Maroto Carrizo, Angelica Valderrama Rodríguez Funding agency: EUROPEAN COMMISSION Funding: 630633.55 Reference: NOCANTHER_H2020NMP2015 Duration: 01/04/2016 - 30/09/2021 Pagination First page « Previous page ‹ Page 1 Page 2 Current page 3
